Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (430)	5/7/1999 4:02:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 717

If I had to guess, I'd say Gadolite was dead, but they don't want to admit it yet. I don't think they have anyone to manufacture it after Glaxo sold the plant that was going to be used for manufacture; there's the threat of a patent suit from Schering; and they now have much bigger fish to fry. Far as I'm concerned it would be nothing but a distraction if they tried to revive it. The H&Q presentation next week is in London - maybe we'll see some European interest. Not sure if they have anything new to present, though. The Antrin (roto-rooter) Phase I trial is now fully enrolled, but it's probably too early to give much of an update on this one though. Interesting that they got full enrollment in this trial real quickly - always a good sign. BTW, if you haven't already, you should check out their excellent web site at pcyc.com . Peter